Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from SAB Biotherapeutics (SABS).
SAB Biotherapeutics has successfully completed the third cohort dosing in phase one trials for their new drug, SAB-142, without any cases of serum sickness reported. The company plans to release a detailed corporate update mid-April, which could be a significant point of interest for investors and followers of the biotech industry.
For an in-depth examination of SABS stock, go to TipRanks’ Stock Analysis page.
